Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 8;85(13):1455-1458.
doi: 10.1016/j.jacc.2025.01.033. Epub 2025 Mar 17.

Systolic Blood Pressure and Cardiovascular Mortality in U.S. Adults Aged 80+ Taking Antihypertensive Medications

Huanhuan Yang  1 , Chenxi Huang  2 , Mitsuaki Sawano  2 , Jeph Herrin  3 , Guochong Chen  4 , Zhihui Li  5 , Erica S Spatz  2 , Harlan M Krumholz  6 , Yuan Lu  7
Affiliations

Systolic Blood Pressure and Cardiovascular Mortality in U.S. Adults Aged 80+ Taking Antihypertensive Medications

Huanhuan Yang et al. J Am Coll Cardiol. .
No abstract available

Keywords: cardiovascular mortality; hypertension; older adults; systolic blood pressure.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures This work was supported by the National Heart, Lung, and Blood Institute (grant Nos. R01HL169954). Dr Spatz has received funding from the Centers for Disease Control and Prevention (20042801-Sub01), the National Heart, Lung, and Blood Institute (R01HL151240), and the Patient Centered Outcomes Research Institute (HM-2022C2-28354). Dr Krumholz, in the past 3 years, has received options for Element Science and Identifeye; has received payments from F-Prime for advisory roles; is a co-founder of and holds equity in Hugo Health, Refactor Health, and ENSIGHTAI; and is associated with research contracts through Yale University from Janssen, Kenvue, Novartis, and Pfizer. Dr Lu has received support from the Sentara Research Foundation, the National Heart, Lung, and Blood Institute (grant Nos. R01HL169954, R01HL169 171), and the Patient-Centered Outcomes Research Institute (No. HM-2022C2-28354). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

Figure.
Figure.
Association between Systolic Blood Pressure and CVD-cause Mortality among Adults Aged 80 or Older with Anti-hypertensive Medication Use from NHANES 1988 to 2014 in the U.S. Figure illustrates the association between systolic blood pressure and CVD-cause mortality among a nationally representative sample of older adults with anti-hypertensive medication use. (A) Hazard Ratios (HR) and 95% Confidence Intervals (CI) are plotted across a range of blood pressure values in Cox models with penalized spline. The dashed lines at 97.8 mmHg and 130.8 mmHg represent the range where the HR, with its 95% confidence interval, is below 1.0. In contrast, the SBP range from 145.0 to 171.8 mmHg represents the period where the HR, with its 95% confidence interval, is above 1.0. (B) Kaplan–Meier survival analysis stratified by low (<130 mm Hg), middle (130–160 mm Hg), and high (>160 mm Hg) systolic blood pressure levels in the Cox proportional hazards model. All analysis adjusted for sex, ethnicity, education level, smoking status, anti-diabetic drug, anti-lipid drug, self-reported of heart failure, stroke, and myocardial infarction.
See this image and copyright information in PMC

References

    1. Prevention CfDCa. CDC Wonder. 2021. Census population projections. Accessed May 3, 2022. https://wonder.cdc.gov/population.html.
    1. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93–e621. doi:10.1161/cir.0000000000001123 - DOI - PubMed
    1. Zhang W, Zhang S, Deng Y, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385(14):1268–1279. doi:10.1056/NEJMoa2111437 - DOI - PubMed
    1. Tate Kienzle AOA, MD; Matasic Daniel, MD; Burka Semenawit, MD; Blumenthal Roger S., MD, FACC. New Blood Pressure Target For Individuals at High Risk. 2024;
    1. Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. Bmj. 2011;344:d7541. doi:10.1136/bmj.d7541 - DOI - PubMed

LinkOut - more resources